Endothelial DysfunctionNCT05014659
Creatine Monohydrate Supplementation and Vascular Endothelial Health
A study testing Creatine monohydrate in people with Endothelial Dysfunction and Oxidative Stress, run by Florida State University at 1 site in United States.
Trial summary
To determine the effects of 4 weeks of creatine monohydrate supplementation on markers of macrovascular and microvascular function, cognitive performance, and physical performance. Read more about this study
- Who is it for?
- Ages 50 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Endothelial Dysfunction, Oxidative Stress
- What is being tested?
- Creatine monohydrate
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Oct 2020to 12 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- both male and female
- 50-64 years old
- no restrictions based on race, ethnicity, or socioeconomic status
- sedentary individuals (<20 minutes; <3 days/wk. physical activity)
- post-menopausal women (has experienced 12 consecutive months without menstruation for >5 years).
Who cannot join
- <50 or ≥65 years of age
- Subjects participating in regular exercise (>20 min/day, >3 days/week)
- female subjects who are pregnant, lactating or 1 month post-partum
- currently consuming or had consumed creatine supplementation <1 month prior to screening
- currently consuming or consumed nitric oxide supplementation <1 month prior to screening
- currently consuming or had consumed Vitamin C supplementation <2 weeks prior to screening
Show all 17Show fewer
- individuals who report chronic infections
- individuals reporting paralysis due to stroke
- individuals reporting advanced Parkinson's disease
- individuals reporting severe rheumatoid arthritis or other serious orthopedic problems that would prevent performance of the exercise tasks
- individuals currently taking medications that may affect central or peripheral circulation
- individuals with known cardiovascular and/or metabolic disease
- current smokers or those who quit <6 months prior to screening
- individuals with hypercholesterolemia (total cholesterol > 200mg/dL, high density lipoprotein <40 mg/dL, low density lipoprotein >130mg/dL)
- individuals with hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure >95mmHg).
- individuals with known kidney disease
- individuals with known liver disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Impact of Creatine Supplementation on Vascular Endothelial Function, Blood Flow and Functional Exercise Capacity
To determine the effects of 4 weeks of creatine monohydrate supplementation on markers of macrovascular and microvascular function, cognitive performance, and physical performance.
Read the detailed description
This is a randomized, double-blind (participant and principle investigator), placebo-controlled, crossover study.
After a pre-screen telephone interview, potential participants will be invited to Florida State University for a "Screening visit". During this visit, individuals will be provided with a verbal and written explanation of the study. Individuals will complete an informed consent, a health history questionnaire and physical activity readiness questionnaire. If they meet study inclusion criteria, they will undergo anthropometric measurements and a venous blood draw to determine cardiovascular and kidney disease risk profile. If cleared for participation, participants will be asked to complete a "3-Day Food Log" prior to their next visit.
Once qualified, participants will return to the laboratory to undergo their "Baseline Testing Visit". Following the completion of the first "Baseline Testing Visit", participants will be randomly assigned to one of two interventions: 1) creatine monohydrate; or, 2) maltodextrin "placebo". Participants will be given their supplement and asked to complete the supplementation protocol, complying with instructions given. Following the 4-week supplementation period, participants will return to the laboratory for their "Post-Supplement #1 Testing". During this visit, all procedures from the "Baseline Testing Visit" will be repeated.
Once these measurements are completed, participants will be asked to return to their normal daily lifestyles for a 4-week "wash-out" period. During these 4-weeks, participants will be contacted weekly to ensure retention and to schedule the next visit. Following the washout, participants will return to the laboratory to undergo another "Baseline Testing Visit", completing the exact procedures as outlined previously. Following this, participants will be given their remaining supplement intervention. Following the intervention, participants will return to the lab for their final "Post-Supplement #2 Testing" to conclude the study.
- Conditions
- Endothelial Dysfunction, Oxidative Stress
- Being tested
- Creatine monohydrate, Placebo
- Keywords
- Older adults, Flow mediated dilation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Creatine monohydrateDietary supplement
4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
PlaceboDietary supplement
Also called Maltodextrin
4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
| Study group | Role | What they receive |
|---|---|---|
| Creatine monohydrate | Experimental | Participants received 4 x 5g doses of creatine monohydrate (powdered form) for 5 days, followed by 1 x 5g doses of creatine monohydrate (powdered form) for 23 days. Receives: Dietary Supplement: Creatine monohydrate |
| Placebo | Placebo comparator | Participants received 4 x 5g doses of placebo (powdered Maltodextrin) for 5 days, followed by 1 x 5g doses of placebo (powdered Maltodextrin) for 23 days. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in brachial artery flow mediated dilation (FMD%) at week 4
FMD% is a validated, non-invasive, standardized method of measuring the ability of an artery to respond to a stimulated increase in blood flow via vasodilation. Increase in blood flow will be stimulated by inflating a forearm cuff for 5 minutes, then rapidly releasing this cuff. Brachial artery in the participants right arm will be identified/imaged using a Philips Doppler Ultrasound. Resting diameter will be measured in millimeters, and max dilation will be the maximum diameter in millimeters following increased blood flow (cuff release). FMD% will be calculated by [(max diameter - resting diameter) / resting diameter] x 100.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in forearm microvascular reperfusion rate (%/sec) at week 4
Microvascular reperfusion rate will be assessed using a near-infrared spectroscopy (NIRS) unit placed on the forearm during the FMD assessment. This small, non-invasive NIRS unit will allow for the determination of forearm muscle tissue oxygen saturation during FMD. The microvascular reperfusion rate (%/sec) will be determined by analyzing the upward slope of tissue saturation following FMD cuff release.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in brachial-ankle pulse wave velocity (baPWV) at week 4
PWV is a validated, non-invasive, clinical technique used to measure arterial stiffness. Participants will lay supine, and 4 blood pressure cuffs will be wrapped around the limbs. One cuff on each arm (brachial artery) and one cuff on each ankle (posterior tibial artery). The distance between the two sampling points (arms and ankles) will be calculated according to the height of the subject. PWV is measured as the distance between two recording sites divided by the transit time of the pulse wave detected. PWV will be given as meters/second.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in augmentation (AUG) and augmentation index (AIx) using pulse wave analysis (PWA) at week 4
Both AUG and AIx are determined based on waveforms captured using a pulse wave analysis device (PWA). PWA is a validated, non-invasive technique used to determine central arterial stiffness via the assessment of the radial pulse (wrist). PWA will be measured using a tonometer which is gently pressed against the radial pulse point. Ten seconds of high-quality waveforms will be captured and analyzed to determine AUG (the pressure added to the forward wave by the reflected wave; measured in mmHg) and AIx (a measure of the effect of the wave reflection on the second systolic peak; expressed as a %).
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in oxidized low density lipoprotein (oxLDL) at week 4
OxLDL is a commonly used, validated, blood biomarker of lipid oxidation. OxLDL is thereby indicative of oxidative stress. A small amount of venous blood will be drawn (~5ml) at the beginning of every visit, centrifuged, and then stored in a -80 freezer. Plasma will later be used to analyze levels of OxLDL using a commercially available enzyme-linked immunoassay.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in tetrahydrobiopterin (BH4) at week 4
BH4 is a very important cofactor necessary for the natural production of nitric oxide - a substance produced by the body and majorly responsible for the vasodilation (increase in diameter) of major arteries, such as the brachial artery. BH4 has been shown to decrease with age and with higher levels of systemic oxidative stress. A small amount of venous blood will be drawn (~5ml) at the beginning of every visit, centrifuged, and then stored in a -80 freezer. Plasma will then later be used to analyze levels of BH4 using a commercially available enzyme-linked immunoassay.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in malondialdehyde (MDA) at week 4
MDA is a commonly used, validated, blood biomarker of oxidative stress. A small amount of venous blood will be drawn (~5ml) at the beginning of every visit, centrifuged, and then stored in a -80 freezer. Plasma will then later be used to analyze levels of MDA using a commercially available enzyme-linked immunoassay.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in total 6-minute walking distance (6MWT) at week 4
The 6 minute walk test (6MWT) assesses distance walked over 6 minutes as a sub-maximal test of aerobic capacity/endurance. The participant will be asked to walk on a pre-measured track for a total of 6 minutes, and total distance covered will be measured in meters following completion.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in total torque produced (total Nm) per set at week 4
In order to assess physical performance, participants will perform right knee extension and flexion for a total of 3 sets, each consisting of 30 repetitions, with 1 minute recovery between each set. This assessment will be carried out on a Biodex Isokinetic Dynamometer, which will track force produced in Newton meters (Nm) for each repetition. For each individual set, the peak torque of each repetition will be summed, and this value will be used to represent isokinetic performance. This data will be presented as total newton-meters (Nm) produced per set.
Change = Week 4 Set 1 Score - Baseline Set 1 Score Week 4 Set 2 Score - Baseline Set 2 Score Week 4 Set 3 Score - Baseline Set 3 Score
Measured: Baseline and Week 4
Change from baseline in time taken to complete (seconds) the Trail Making Test (TMT) at Week 4
The TMT is a measurement of visual attention and task switching and has been validated for its use in neuropsychological assessment. Both parts of the TMT (Part A + Part B) consist of 25 circles distributed over a sheet of white paper. In Part A of the TMT, circles are numbered 1 - 25, and the participant will be instructed to connect numbers consecutively in ascending order (ex. 1,2,3,4…). In Part B of the TMT, circles include both numbers (1 - 13) and letters (A - L). Participants will also be asked to draw lines to connect these circles in an ascending manner, but with the added task of alternating between numbers and letters (ex. 1-A-2-B-3-C…). During both trials the participant will be asked to connect the circles as quickly as possible. Time taken to complete each trial (Part A + Part B) will be recorded (seconds).
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in maximum number recall (#) achieved in the Digit Span memory recall test at Week 4
A digit span (DS) memory recall test will be used to assess short-term memory. Both forward and backward DS testing remains one of the most widely utilized neuropsychological tests used to assess short-term verbal memory. Participants will complete both a forward-DS (FDS) and a backward-DS (BDS) test. Participants will be read a sequence of numbers at a rate of 1 digit/second, in a monotonous and clear tone. Each sequence will vary in length, from 2 numbers to 9 numbers. Participants will have 2 attempts to successfully repeat the sequence of numbers. The test will be discontinued after the failure to repeat a sequence on both attempts. Following this, participants will complete a BDS. Numbers will now have to be repeated backwards by the participant. Both digit span tests will be scored and reported separately as "span scores" (the maximum number of digits correctly produced forward or backwards by the participant).
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Secondary outcomes (6)
Change from baseline in body fat percent (BF%) at week 4
Body fat %, or the percent of an individuals body weight that is fat mass, will be determined using a dual-energy X-ray absorptiometry (DXA) scan. Participants will lay supine on the DXA table, and be scanned from head to toe. This procedure involves a minimal amount of radiation that is within an acceptable range. The amount of radiations per scan is less than one tenth of the amount used during a normal chest x-ray and equivalent to one day of exposure to natural background radiation. The amount of radiation used during a DXA scan is considered safe for adults. BF% will then be determined by the DXA computer software.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in body lean mass (grams) at week 4
Lean mass, or the amount in grams of an individuals body weight that is composed of lean tissue such as muscle, will be determined using a dual-energy X-ray absorptiometry (DXA) scan. Participants will lay supine on the DXA table, and be scanned from head to toe. This procedure involves a minimal amount of radiation that is within an acceptable range. The amount of radiations per scan is less than one tenth of the amount used during a normal chest x-ray and equivalent to one day of exposure to natural background radiation. The amount of radiation used during a DXA scan is considered safe for adults. Lean mass (g) will then be determined by the DXA computer software.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in body fat mass (grams) at week 4
Fat mass, or the amount in grams of an individuals body weight that is composed of fat tissue such as visceral fat, will be determined using a dual-energy X-ray absorptiometry (DXA) scan. Participants will lay supine on the DXA table, and be scanned from head to toe. This procedure involves a minimal amount of radiation that is within an acceptable range. The amount of radiations per scan is less than one tenth of the amount used during a normal chest x-ray and equivalent to one day of exposure to natural background radiation. The amount of radiation used during a DXA scan is considered safe for adults. Fat mass (g) will then be determined by the DXA computer software.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in total body water (liters) at week 4
The total amount of body water will be determined by using a Bioelectrical Impedance Analysis device (BIS). BIS works by having subjects lay supine whilst electrodes are placed on both the right ankle and right wrist. A low level, imperceptible electrical current is then sent through the body, travelling from electrode A to electrode B. The flow of the current is affected by the amount of water in the body; therefore the BIS can estimate how much water is present in the body (liters). Furthermore, this total amount will then be categorized as either intracellular fluid (fluid found within cells) or extracellular fluid (fluid found outside cells). This BIS will be used to measure any possible fluids shifts.
Change = Week 4 Score - Baseline Score
Measured: Baseline and Week 4
Change from baseline in resting systolic blood pressure (mmHg) at week 4
Resting systolic blood pressure will be measured following 10 minutes of laying supine in a temperature controlled, dimly lit room, using a commercially available automatic blood pressure device (Omron).
Change = Week 4 Score - Baseline
Measured: Baseline and Week 4
Change from baseline in resting diastolic blood pressure (mmHg) at week 4
Resting diastolic blood pressure will be measured following 10 minutes of laying supine in a temperature controlled, dimly lit room, using a commercially available automatic blood pressure device (Omron).
Change = Week 4 Score - Baseline
Measured: Baseline and Week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2021
- Study start17 Oct 2020
- Primary completion12 Dec 2022
- Study completion12 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Endothelial DysfunctionStudies of the same condition, open and under way.
- More trials run by Florida State UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Florida State University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Holly Clarke, Florida State University
- Investigators
- Holly E Clarke, PhD, Principal investigator, Florida State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05014659
- Sponsor's protocol ID
- STUDY00000764
- Status last verified
- Jan 2023
- First submitted
- 19 Aug 2021
- Last updated
- 13 Jan 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Participant data will not be shared with anyone who is not an approved research team member, as indicated in this study's Florida State University Institutional Review Board document.
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Creatine Supplementation on Vascular Endothelial Function, Blood Flow and Functional Exercise Capacity
- ClinicalTrials.gov ID
- NCT05014659
- Acronym / sponsor ID
- STUDY00000764
- Conditions
- Endothelial Dysfunction, Oxidative Stress
- Keywords
- Older adults, Flow mediated dilation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Florida State UniversityUniversity, hospital or other
- Study start
- 17 Oct 2020 (actual)
- Primary completion
- 12 Dec 2022 (actual)
- Study completion
- 12 Dec 2022 (actual)
- First posted
- 20 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the effects of 4 weeks of creatine monohydrate supplementation on markers of macrovascular and microvascular function, cognitive performance, and physical performance.
Detailed description
This is a randomized, double-blind (participant and principle investigator), placebo-controlled, crossover study.
After a pre-screen telephone interview, potential participants will be invited to Florida State University for a "Screening visit". During this visit, individuals will be provided with a verbal and written explanation of the study. Individuals will complete an informed consent, a health history questionnaire and physical activity readiness questionnaire. If they meet study inclusion criteria, they will undergo anthropometric measurements and a venous blood draw to determine cardiovascular and kidney disease risk profile. If cleared for participation, participants will be asked to complete a "3-Day Food Log" prior to their next visit.
Once qualified, participants will return to the laboratory to undergo their "Baseline Testing Visit". Following the completion of the first "Baseline Testing Visit", participants will be randomly assigned to one of two interventions: 1) creatine monohydrate; or, 2) maltodextrin "placebo". Participants will be given their supplement and asked to complete the supplementation protocol, complying with instructions given. Following the 4-week supplementation period, participants will return to the laboratory for their "Post-Supplement #1 Testing". During this visit, all procedures from the "Baseline Testing Visit" will be repeated.
Once these measurements are completed, participants will be asked to return to their normal daily lifestyles for a 4-week "wash-out" period. During these 4-weeks, participants will be contacted weekly to ensure retention and to schedule the next visit. Following the washout, participants will return to the laboratory to undergo another "Baseline Testing Visit", completing the exact procedures as outlined previously. Following this, participants will be given their remaining supplement intervention. Following the intervention, participants will return to the lab for their final "Post-Supplement #2 Testing" to conclude the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Creatine monohydrate | Experimental | Dietary Supplement: Creatine monohydrateParticipants received 4 x 5g doses of creatine monohydrate (powdered form) for 5 days, followed by 1 x 5g doses of creatine monohydrate (powdered form) for 23 days. |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboParticipants received 4 x 5g doses of placebo (powdered Maltodextrin) for 5 days, followed by 1 x 5g doses of placebo (powdered Maltodextrin) for 23 days. |
Who may qualify
- Ages
- 50 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- both male and female
- 50-64 years old
- no restrictions based on race, ethnicity, or socioeconomic status
- sedentary individuals (<20 minutes; <3 days/wk. physical activity)
- post-menopausal women (has experienced 12 consecutive months without menstruation for >5 years).
Key exclusion criteria (17 listed)
- <50 or ≥65 years of age
- Subjects participating in regular exercise (>20 min/day, >3 days/week)
- female subjects who are pregnant, lactating or 1 month post-partum
- currently consuming or had consumed creatine supplementation <1 month prior to screening
- currently consuming or consumed nitric oxide supplementation <1 month prior to screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Creatine monohydrate4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days. | Dietary supplement | Creatine monohydrate |
| PlaceboAlso: Maltodextrin4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days. | Dietary supplement | Placebo |
Primary outcome
Change from baseline in brachial artery flow mediated dilation (FMD%) at week 4
Time frame: Baseline and Week 4
FMD% is a validated, non-invasive, standardized method of measuring the ability of an artery to respond to a stimulated increase in blood flow via vasodilation. Increase in blood flow will be stimulated by inflating a forearm cuff for 5 minutes, then rapidly releasing this cuff. Brachial artery in the participants right arm will be identified/imaged using a Philips Doppler Ultrasound. Resting diameter will be measured in millimeters, and max dilation will be the maximum diameter in millimeters following increased blood flow (cuff release). FMD% will be calculated by [(max diameter - resting diameter) / resting diameter] x 100. Change = Week 4 Score - Baseline Score
Change from baseline in forearm microvascular reperfusion rate (%/sec) at week 4
Time frame: Baseline and Week 4
Microvascular reperfusion rate will be assessed using a near-infrared spectroscopy (NIRS) unit placed on the forearm during the FMD assessment. This small, non-invasive NIRS unit will allow for the determination of forearm muscle tissue oxygen saturation during FMD. The microvascular reperfusion rate (%/sec) will be determined by analyzing the upward slope of tissue saturation following FMD cuff release. Change = Week 4 Score - Baseline Score
Change from baseline in brachial-ankle pulse wave velocity (baPWV) at week 4
Time frame: Baseline and Week 4
PWV is a validated, non-invasive, clinical technique used to measure arterial stiffness. Participants will lay supine, and 4 blood pressure cuffs will be wrapped around the limbs. One cuff on each arm (brachial artery) and one cuff on each ankle (posterior tibial artery). The distance between the two sampling points (arms and ankles) will be calculated according to the height of the subject. PWV is measured as the distance between two recording sites divided by the transit time of the pulse wave detected. PWV will be given as meters/second. Change = Week 4 Score - Baseline Score
Change from baseline in augmentation (AUG) and augmentation index (AIx) using pulse wave analysis (PWA) at week 4
Time frame: Baseline and Week 4
Both AUG and AIx are determined based on waveforms captured using a pulse wave analysis device (PWA). PWA is a validated, non-invasive technique used to determine central arterial stiffness via the assessment of the radial pulse (wrist). PWA will be measured using a tonometer which is gently pressed against the radial pulse point. Ten seconds of high-quality waveforms will be captured and analyzed to determine AUG (the pressure added to the forward wave by the reflected wave; measured in mmHg) and AIx (a measure of the effect of the wave reflection on the second systolic peak; expressed as a %). Change = Week 4 Score - Baseline Score
Change from baseline in oxidized low density lipoprotein (oxLDL) at week 4
Time frame: Baseline and Week 4
OxLDL is a commonly used, validated, blood biomarker of lipid oxidation. OxLDL is thereby indicative of oxidative stress. A small amount of venous blood will be drawn (~5ml) at the beginning of every visit, centrifuged, and then stored in a -80 freezer. Plasma will later be used to analyze levels of OxLDL using a commercially available enzyme-linked immunoassay. Change = Week 4 Score - Baseline Score
Change from baseline in tetrahydrobiopterin (BH4) at week 4
Time frame: Baseline and Week 4
BH4 is a very important cofactor necessary for the natural production of nitric oxide - a substance produced by the body and majorly responsible for the vasodilation (increase in diameter) of major arteries, such as the brachial artery. BH4 has been shown to decrease with age and with higher levels of systemic oxidative stress. A small amount of venous blood will be drawn (~5ml) at the beginning of every visit, centrifuged, and then stored in a -80 freezer. Plasma will then later be used to analyze levels of BH4 using a commercially available enzyme-linked immunoassay. Change = Week 4 Score - Baseline Score
Change from baseline in malondialdehyde (MDA) at week 4
Time frame: Baseline and Week 4
MDA is a commonly used, validated, blood biomarker of oxidative stress. A small amount of venous blood will be drawn (~5ml) at the beginning of every visit, centrifuged, and then stored in a -80 freezer. Plasma will then later be used to analyze levels of MDA using a commercially available enzyme-linked immunoassay. Change = Week 4 Score - Baseline Score
Change from baseline in total 6-minute walking distance (6MWT) at week 4
Time frame: Baseline and Week 4
The 6 minute walk test (6MWT) assesses distance walked over 6 minutes as a sub-maximal test of aerobic capacity/endurance. The participant will be asked to walk on a pre-measured track for a total of 6 minutes, and total distance covered will be measured in meters following completion. Change = Week 4 Score - Baseline Score
Change from baseline in total torque produced (total Nm) per set at week 4
Time frame: Baseline and Week 4
In order to assess physical performance, participants will perform right knee extension and flexion for a total of 3 sets, each consisting of 30 repetitions, with 1 minute recovery between each set. This assessment will be carried out on a Biodex Isokinetic Dynamometer, which will track force produced in Newton meters (Nm) for each repetition. For each individual set, the peak torque of each repetition will be summed, and this value will be used to represent isokinetic performance. This data will be presented as total newton-meters (Nm) produced per set. Change = Week 4 Set 1 Score - Baseline Set 1 Score Week 4 Set 2 Score - Baseline Set 2 Score Week 4 Set 3 Score - Baseline Set 3 Score
Change from baseline in time taken to complete (seconds) the Trail Making Test (TMT) at Week 4
Time frame: Baseline and Week 4
The TMT is a measurement of visual attention and task switching and has been validated for its use in neuropsychological assessment. Both parts of the TMT (Part A + Part B) consist of 25 circles distributed over a sheet of white paper. In Part A of the TMT, circles are numbered 1 - 25, and the participant will be instructed to connect numbers consecutively in ascending order (ex. 1,2,3,4…). In Part B of the TMT, circles include both numbers (1 - 13) and letters (A - L). Participants will also be asked to draw lines to connect these circles in an ascending manner, but with the added task of alternating between numbers and letters (ex. 1-A-2-B-3-C…). During both trials the participant will be asked to connect the circles as quickly as possible. Time taken to complete each trial (Part A + Part B) will be recorded (seconds). Change = Week 4 Score - Baseline Score
Change from baseline in maximum number recall (#) achieved in the Digit Span memory recall test at Week 4
Time frame: Baseline and Week 4
A digit span (DS) memory recall test will be used to assess short-term memory. Both forward and backward DS testing remains one of the most widely utilized neuropsychological tests used to assess short-term verbal memory. Participants will complete both a forward-DS (FDS) and a backward-DS (BDS) test. Participants will be read a sequence of numbers at a rate of 1 digit/second, in a monotonous and clear tone. Each sequence will vary in length, from 2 numbers to 9 numbers. Participants will have 2 attempts to successfully repeat the sequence of numbers. The test will be discontinued after the failure to repeat a sequence on both attempts. Following this, participants will complete a BDS. Numbers will now have to be repeated backwards by the participant. Both digit span tests will be scored and reported separately as "span scores" (the maximum number of digits correctly produced forward or backwards by the participant). Change = Week 4 Score - Baseline Score
6 secondary outcomes
Change from baseline in body fat percent (BF%) at week 4
Time frame: Baseline and Week 4
Change from baseline in body lean mass (grams) at week 4
Time frame: Baseline and Week 4
Change from baseline in body fat mass (grams) at week 4
Time frame: Baseline and Week 4
Change from baseline in total body water (liters) at week 4
Time frame: Baseline and Week 4
Change from baseline in resting systolic blood pressure (mmHg) at week 4
Time frame: Baseline and Week 4
Change from baseline in resting diastolic blood pressure (mmHg) at week 4
Time frame: Baseline and Week 4
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2023.
- Individual participant dataSharing planned: No. Participant data will not be shared with anyone who is not an approved research team member, as indicated in this study's Florida State University Institutional Review Board document.
Related trials for Endothelial Dysfunction
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Active, not recruiting
Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function
Obesity, Weight Loss
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
RecruitingPhase 2
Spironolactone for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Not yet recruiting
Effect of Propionic Acid Supplementation on Endothelial Function
Cardiovascular Diseases, Endothelial Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Holly E Clarke, PhD principal investigator
Florida State University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Creatine monohydrate in people with Endothelial Dysfunction and Oxidative Stress, run by Florida State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in brachial artery flow mediated dilation (FMD%) at week 4 (time frame: Baseline and Week 4). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2023.